<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00482547</url>
  </required_header>
  <id_info>
    <org_study_id>BMD-6003</org_study_id>
    <nct_id>NCT00482547</nct_id>
  </id_info>
  <brief_title>Study of a Urethral Catheter Coated With Eluting Silver Salts (SUCCESS)</brief_title>
  <acronym>SUCCESS</acronym>
  <official_title>Study of a Urethral Catheter Coated With Eluting Silver Salts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urinary catheters are often needed in hospital patients, but their use can increase the
      chance that a catheter associated urinary tract infection (called a CAUTI) may occur. This
      study will try to determine if patients who get a new silver coated catheter will have slower
      to time to development of a CAUTI compared to patients who get an uncoated catheter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, multicenter, randomized controlled pivotal study designed to
      compare the time to occurrence and incidence of CAUTI in subjects catheterized with a new
      hydrogel-silver salts latex catheter (test) to those of subjects catheterized with a silicone
      elastomer-coated latex catheter (control).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated for futility reasons.
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Occurrence of Bacteriuric Urinary Tract Infection (bUTI) in Subjects Catheterized for &gt;= 48 Hours</measure>
    <time_frame>&gt;=48 hours to 10 days</time_frame>
    <description>Time to occurrence of bUTI in subjects of both study groups who were catheterized with a study catheter for &gt;= 48 hours and who had evidence of bUTI after study catheter insertion. Subjects who did not have a bUTI are not included in the median calculation, so the median only includes data from non-censored observations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a bUTI After Catheterization for &gt;= 48 Hours</measure>
    <time_frame>&gt;=48 hours to 10 days</time_frame>
    <description>The percentage of bUTI was calculated as the rate of new occurrence of bUTI in subjects of both study groups who had been catheterized with a study catheter for &gt;= 48 hours and who did not have evidence of bUTI at the time of study catheter insertion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Occurence of Symptomatic Urinary Tract Infection (sUTI) in Subjects Catheterized for &gt;= 48 Hours</measure>
    <time_frame>&gt;= 48 hours to 10 days</time_frame>
    <description>The time to occurrence of sUTI was measured as the time between catheter insertion and when the criteria for sUTI was met, up to 10 days after catheterization plus 48 hours after catheter removal. Subjects who did not have a sUTI are not included in the median calculation, so the median only includes data from non-censored observations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Occurence of bUTI in Subjects Catheterized for &gt;= 24 Hours</measure>
    <time_frame>&gt;= 24 hours to 10 days</time_frame>
    <description>Time to occurrence of bUTI in subjects of both study groups who were catheterized with a study catheter for &gt;= 24 hours and developed a bUTI at after catheter insertion. Subjects who did not have a bUTI are not included in the median calculation, so the median only includes data from non-censored observations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Occurance of sUTI in Subjects Catheterized for &gt;= 24 Hours</measure>
    <time_frame>&gt;= 24 hours to 10 days</time_frame>
    <description>The time to occurrence of sUTI was measured as the time between catheter insertion and when the criteria for sUTI was met, up to 10 days after catheterization plus 48 hours after catheter removal. Subjects who did not have a sUTI are not included in the median calculation, so the median only includes data from non-censored observations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bacteriuria at a Concentration of ≥ 10e3 &lt; 10e5 CFU/mL</measure>
    <time_frame>10 days</time_frame>
    <description>The number of subjects with bacteriuria levels ≥ 10e3 &lt; 10e5 CFU/mL who subsequently developed a bUTI or a sUTI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Subjects With a bUTI Catheterized for &gt;=48 Hours.</measure>
    <time_frame>From time of catheterization until 10 days post catheterization or 48 hours after catheter removal.</time_frame>
    <description>bUTI occurences were counted in subjects of both study groups who had been catheterized with a study catheter for &gt;= 48 hours and who did not have evidence of bUTI at the time of study catheter insertion.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Subjects With a sUTI Catheterized for &gt;=48 Hours.</measure>
    <time_frame>From time of catheterization until 10 days or 48 hours after catheter was removed</time_frame>
    <description>sUTI occurences were counted in subjects of both study groups who had been catheterized with a study catheter for &gt;= 48 hours and who did not have evidence of bUTI at the time of study catheter insertion.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1188</enrollment>
  <condition>Catheterization</condition>
  <arm_group>
    <arm_group_label>Silver-coated catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bard Hydrogel Silver Salts Coated Latex Urinary Catheter System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Silicone-coated catheter</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bard silicone elastomer coated latex catheter system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrogel Silver Salts Coated Latex Urinary Catheter System</intervention_name>
    <description>Silver-coated catheter</description>
    <arm_group_label>Silver-coated catheter</arm_group_label>
    <other_name>AgSC arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bard silicone elastomer coated latex catheter system</intervention_name>
    <description>Silicone-coated catheter</description>
    <arm_group_label>Silicone-coated catheter</arm_group_label>
    <other_name>SiCS arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female at least 18 years of age

          -  life expectancy of 3 months or more

          -  expected to require a urinary catheter for at least 48 hours

        Exclusion Criteria:

          -  recent urinary tract surgery or instrumentation

          -  presence of a urinary tract device

          -  concurrent genitourinary tract infection

          -  recent indwelling urinary catheter

          -  requires use of a non-study urinary catheter
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Rupp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2007</study_first_submitted>
  <study_first_submitted_qc>June 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2007</study_first_posted>
  <results_first_submitted>April 6, 2009</results_first_submitted>
  <results_first_submitted_qc>December 17, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 21, 2010</results_first_posted>
  <last_update_submitted>January 13, 2017</last_update_submitted>
  <last_update_submitted_qc>January 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>urinary tract infection</keyword>
  <keyword>urinary catheter</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Twenty Investigators at 20 Investigative Sites enrolled a total of 1188 study subjects between June 28, 2007 and June 23, 2008.</recruitment_details>
      <pre_assignment_details>Subjects judged by site personnel to require a urinary catheter for at least 48-72 hours were screened against the study inclusion/exclusion criteria. Those subjects meeting these criteria were offered participation in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Silver-coated Catheter</title>
          <description>Bard® Hydrogel Silver Salts Coated Latex Urinary Catheter</description>
        </group>
        <group group_id="P2">
          <title>Silicone-coated Catheter</title>
          <description>silicone elastomer-coated latex catheter</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="599">599 subjects were enrolled in the silver-coated catheter group.</participants>
                <participants group_id="P2" count="589">589 subjects were enrolled in the silicone-coated catheter group.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Successful Catheterization</title>
              <participants_list>
                <participants group_id="P1" count="565">Out of the 599 AgCS subjects 565 (94.3%) had a successful catheterization.</participants>
                <participants group_id="P2" count="568">Out of the 589 SiCS catheter subjects 568 (96.4%) had a successful catheterization.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>48 Hour Evaluation</title>
              <participants_list>
                <participants group_id="P1" count="426">426 went on to be included in the Silver-coated 48 hour efficacy evaluable population.</participants>
                <participants group_id="P2" count="428">428 went on to be included in the Silicone-coated 48 hour efficacy evaluable population.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="426"/>
                <participants group_id="P2" count="428"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="173"/>
                <participants group_id="P2" count="161"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Silver-coated Catheter</title>
          <description>Bard® Hydrogel Silver Salts Coated Latex Urinary Catheter</description>
        </group>
        <group group_id="B2">
          <title>Silicone-coated Catheter</title>
          <description>silicone elastomer-coated latex catheter</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="599"/>
            <count group_id="B2" value="589"/>
            <count group_id="B3" value="1188"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="302"/>
                    <measurement group_id="B2" value="287"/>
                    <measurement group_id="B3" value="589"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="297"/>
                    <measurement group_id="B2" value="302"/>
                    <measurement group_id="B3" value="599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="15.9"/>
                    <measurement group_id="B2" value="64.3" spread="14.5"/>
                    <measurement group_id="B3" value="64.0" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="341"/>
                    <measurement group_id="B2" value="332"/>
                    <measurement group_id="B3" value="673"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="258"/>
                    <measurement group_id="B2" value="257"/>
                    <measurement group_id="B3" value="515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="599"/>
                    <measurement group_id="B2" value="589"/>
                    <measurement group_id="B3" value="1188.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a bUTI After Catheterization for &gt;= 48 Hours</title>
        <description>The percentage of bUTI was calculated as the rate of new occurrence of bUTI in subjects of both study groups who had been catheterized with a study catheter for &gt;= 48 hours and who did not have evidence of bUTI at the time of study catheter insertion.</description>
        <time_frame>&gt;=48 hours to 10 days</time_frame>
        <population>Efficacy Evaluable (48) population: ITT subjects who were catheterized with a study catheter for ≥ 48 hours and who did not have a bUTI in the baseline urine sample obtained at the time of catheter insertion.</population>
        <group_list>
          <group group_id="O1">
            <title>Silver-coated Catheter</title>
            <description>Bard® Hydrogel Silver Salts Coated Latex Urinary Catheter</description>
          </group>
          <group group_id="O2">
            <title>Silicone-coated Catheter</title>
            <description>silicone elastomer-coated latex catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a bUTI After Catheterization for &gt;= 48 Hours</title>
          <description>The percentage of bUTI was calculated as the rate of new occurrence of bUTI in subjects of both study groups who had been catheterized with a study catheter for &gt;= 48 hours and who did not have evidence of bUTI at the time of study catheter insertion.</description>
          <population>Efficacy Evaluable (48) population: ITT subjects who were catheterized with a study catheter for ≥ 48 hours and who did not have a bUTI in the baseline urine sample obtained at the time of catheter insertion.</population>
          <units>Percentage of Participants with a bUTI</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="426"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4"/>
                    <measurement group_id="O2" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Occurrence of Bacteriuric Urinary Tract Infection (bUTI) in Subjects Catheterized for &gt;= 48 Hours</title>
        <description>Time to occurrence of bUTI in subjects of both study groups who were catheterized with a study catheter for &gt;= 48 hours and who had evidence of bUTI after study catheter insertion. Subjects who did not have a bUTI are not included in the median calculation, so the median only includes data from non-censored observations.</description>
        <time_frame>&gt;=48 hours to 10 days</time_frame>
        <population>Efficacy Evaluable (48) population: Intent-to-treat (ITT) subjects who were catheterized with a study catheter for ≥ 48 hours and who developed a bUTI after catheter insertion.</population>
        <group_list>
          <group group_id="O1">
            <title>Silver-coated Catheter</title>
            <description>Bard® Hydrogel Silver Salts Coated Latex Urinary Catheter</description>
          </group>
          <group group_id="O2">
            <title>Silicone-coated Catheter</title>
            <description>silicone elastomer-coated latex catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Occurrence of Bacteriuric Urinary Tract Infection (bUTI) in Subjects Catheterized for &gt;= 48 Hours</title>
          <description>Time to occurrence of bUTI in subjects of both study groups who were catheterized with a study catheter for &gt;= 48 hours and who had evidence of bUTI after study catheter insertion. Subjects who did not have a bUTI are not included in the median calculation, so the median only includes data from non-censored observations.</description>
          <population>Efficacy Evaluable (48) population: Intent-to-treat (ITT) subjects who were catheterized with a study catheter for ≥ 48 hours and who developed a bUTI after catheter insertion.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.10" spread="1.99"/>
                    <measurement group_id="O2" value="2.06" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Occurence of Symptomatic Urinary Tract Infection (sUTI) in Subjects Catheterized for &gt;= 48 Hours</title>
        <description>The time to occurrence of sUTI was measured as the time between catheter insertion and when the criteria for sUTI was met, up to 10 days after catheterization plus 48 hours after catheter removal. Subjects who did not have a sUTI are not included in the median calculation, so the median only includes data from non-censored observations.</description>
        <time_frame>&gt;= 48 hours to 10 days</time_frame>
        <population>Efficacy Evaluable (48) population: ITT subjects who were catheterized with a study catheter for ≥ 48 hours and who developed a sUTI after catheter insertion.</population>
        <group_list>
          <group group_id="O1">
            <title>Silver-coated Catheter</title>
            <description>Bard® Hydrogel Silver Salts Coated Latex Urinary Catheter</description>
          </group>
          <group group_id="O2">
            <title>Silicone-coated Catheter</title>
            <description>silicone elastomer-coated latex catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Occurence of Symptomatic Urinary Tract Infection (sUTI) in Subjects Catheterized for &gt;= 48 Hours</title>
          <description>The time to occurrence of sUTI was measured as the time between catheter insertion and when the criteria for sUTI was met, up to 10 days after catheterization plus 48 hours after catheter removal. Subjects who did not have a sUTI are not included in the median calculation, so the median only includes data from non-censored observations.</description>
          <population>Efficacy Evaluable (48) population: ITT subjects who were catheterized with a study catheter for ≥ 48 hours and who developed a sUTI after catheter insertion.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="1.75"/>
                    <measurement group_id="O2" value="1.62" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Occurence of bUTI in Subjects Catheterized for &gt;= 24 Hours</title>
        <description>Time to occurrence of bUTI in subjects of both study groups who were catheterized with a study catheter for &gt;= 24 hours and developed a bUTI at after catheter insertion. Subjects who did not have a bUTI are not included in the median calculation, so the median only includes data from non-censored observations.</description>
        <time_frame>&gt;= 24 hours to 10 days</time_frame>
        <population>Efficacy Evaluable (24) population: ITT subjects who were catheterized with a study catheter for ≥ 24 hours and who developed a bUTI after catheter insertion.</population>
        <group_list>
          <group group_id="O1">
            <title>Silver-coated Catheter</title>
            <description>Bard® Hydrogel Silver Salts Coated Latex Urinary Catheter</description>
          </group>
          <group group_id="O2">
            <title>Silicone-coated Catheter</title>
            <description>silicone elastomer-coated latex catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Occurence of bUTI in Subjects Catheterized for &gt;= 24 Hours</title>
          <description>Time to occurrence of bUTI in subjects of both study groups who were catheterized with a study catheter for &gt;= 24 hours and developed a bUTI at after catheter insertion. Subjects who did not have a bUTI are not included in the median calculation, so the median only includes data from non-censored observations.</description>
          <population>Efficacy Evaluable (24) population: ITT subjects who were catheterized with a study catheter for ≥ 24 hours and who developed a bUTI after catheter insertion.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="1.98"/>
                    <measurement group_id="O2" value="2.04" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Occurance of sUTI in Subjects Catheterized for &gt;= 24 Hours</title>
        <description>The time to occurrence of sUTI was measured as the time between catheter insertion and when the criteria for sUTI was met, up to 10 days after catheterization plus 48 hours after catheter removal. Subjects who did not have a sUTI are not included in the median calculation, so the median only includes data from non-censored observations.</description>
        <time_frame>&gt;= 24 hours to 10 days</time_frame>
        <population>Efficacy Evaluable (24) population: ITT subjects who were catheterized with a study catheter for ≥ 24 hours and who developed a bUTI after catheter insertion.</population>
        <group_list>
          <group group_id="O1">
            <title>Silver-coated Catheter</title>
            <description>Bard® Hydrogel Silver Salts Coated Latex Urinary Catheter</description>
          </group>
          <group group_id="O2">
            <title>Silicone-coated Catheter</title>
            <description>silicone elastomer-coated latex catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Occurance of sUTI in Subjects Catheterized for &gt;= 24 Hours</title>
          <description>The time to occurrence of sUTI was measured as the time between catheter insertion and when the criteria for sUTI was met, up to 10 days after catheterization plus 48 hours after catheter removal. Subjects who did not have a sUTI are not included in the median calculation, so the median only includes data from non-censored observations.</description>
          <population>Efficacy Evaluable (24) population: ITT subjects who were catheterized with a study catheter for ≥ 24 hours and who developed a bUTI after catheter insertion.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1039" spread="1.73"/>
                    <measurement group_id="O2" value="1.40" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bacteriuria at a Concentration of ≥ 10e3 &lt; 10e5 CFU/mL</title>
        <description>The number of subjects with bacteriuria levels ≥ 10e3 &lt; 10e5 CFU/mL who subsequently developed a bUTI or a sUTI</description>
        <time_frame>10 days</time_frame>
        <population>Safety population: ITT subjects who were catheterized with a study catheter. This population was used to assess tolerability and safety endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Silver-coated Catheter</title>
            <description>Bard® Hydrogel Silver Salts Coated Latex Urinary Catheter</description>
          </group>
          <group group_id="O2">
            <title>Silicone-coated Catheter</title>
            <description>silicone elastomer-coated latex catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bacteriuria at a Concentration of ≥ 10e3 &lt; 10e5 CFU/mL</title>
          <description>The number of subjects with bacteriuria levels ≥ 10e3 &lt; 10e5 CFU/mL who subsequently developed a bUTI or a sUTI</description>
          <population>Safety population: ITT subjects who were catheterized with a study catheter. This population was used to assess tolerability and safety endpoints.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="565"/>
                <count group_id="O2" value="568"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects With a bUTI Catheterized for &gt;=48 Hours.</title>
        <description>bUTI occurences were counted in subjects of both study groups who had been catheterized with a study catheter for &gt;= 48 hours and who did not have evidence of bUTI at the time of study catheter insertion.</description>
        <time_frame>From time of catheterization until 10 days post catheterization or 48 hours after catheter removal.</time_frame>
        <population>Efficacy Evaluable (48) population: ITT subjects who were catheterized with a study catheter for ≥ 48 hours and who did not have a bUTI in the baseline urine sample obtained at the time of catheter insertion.</population>
        <group_list>
          <group group_id="O1">
            <title>Silver-coated Catheter</title>
            <description>Bard® Hydrogel Silver Salts Coated Latex Urinary Catheter</description>
          </group>
          <group group_id="O2">
            <title>Silicone-coated Catheter</title>
            <description>silicone elastomer-coated latex catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a bUTI Catheterized for &gt;=48 Hours.</title>
          <description>bUTI occurences were counted in subjects of both study groups who had been catheterized with a study catheter for &gt;= 48 hours and who did not have evidence of bUTI at the time of study catheter insertion.</description>
          <population>Efficacy Evaluable (48) population: ITT subjects who were catheterized with a study catheter for ≥ 48 hours and who did not have a bUTI in the baseline urine sample obtained at the time of catheter insertion.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="426"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects With a sUTI Catheterized for &gt;=48 Hours.</title>
        <description>sUTI occurences were counted in subjects of both study groups who had been catheterized with a study catheter for &gt;= 48 hours and who did not have evidence of bUTI at the time of study catheter insertion.</description>
        <time_frame>From time of catheterization until 10 days or 48 hours after catheter was removed</time_frame>
        <population>Efficacy Evaluable (48) population: ITT subjects who were catheterized with a study catheter for ≥ 48 hours and who did not have a bUTI in the baseline urine sample obtained at the time of catheter insertion.</population>
        <group_list>
          <group group_id="O1">
            <title>Silver-coated Catheter</title>
            <description>Bard® Hydrogel Silver Salts Coated Latex Urinary Catheter</description>
          </group>
          <group group_id="O2">
            <title>Silicone-coated Catheter</title>
            <description>silicone elastomer-coated latex catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a sUTI Catheterized for &gt;=48 Hours.</title>
          <description>sUTI occurences were counted in subjects of both study groups who had been catheterized with a study catheter for &gt;= 48 hours and who did not have evidence of bUTI at the time of study catheter insertion.</description>
          <population>Efficacy Evaluable (48) population: ITT subjects who were catheterized with a study catheter for ≥ 48 hours and who did not have a bUTI in the baseline urine sample obtained at the time of catheter insertion.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="426"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time of attempted or successful catheter insertion throughout the period of catheterization with the study catheter and for a period of 48 hours following study catheter removal, or until hospital discharge.</time_frame>
      <desc>AE Definition: any undesirable clinical occurrence in a subject that is related to either the urinary tract, or systemic infection.
All SAEs were collected, as defined in 21 CFR 803.3.</desc>
      <group_list>
        <group group_id="E1">
          <title>Silver-coated Catheter</title>
          <description>Bard® Hydrogel Silver Salts Coated Latex Urinary Catheter</description>
        </group>
        <group group_id="E2">
          <title>Silicone-coated Catheter</title>
          <description>silicone elastomer-coated latex catheter</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cardiac Tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Right Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Enterocutaneous Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Postoperative Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Abdominal Wound Dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Anastomotic Leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Reocclusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Amylase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Blood Creatine Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Lipase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Lactic Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Mobility Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute Myeloid Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Cerebellar Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Syncope Vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Alcohol Withdrawal Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Acute Prerenal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Renal Tubular Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Chylothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Increased Bronchial Secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Obstructive Airways Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Wound Drainage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="565"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sample size calculations required 1244 Efficacy Evaluable 48 subjects, only 854 Efficacy Evaluable 48 subjects were enrolled, which does not allow for a fully powered study and there is the threat of a type II error (false negative result).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Vanessa Dell Clinical Research Scientist</name_or_title>
      <organization>C. R. Bard</organization>
      <phone>908-277-8094</phone>
      <email>vanessa.dell@crbard.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

